T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies

• Published in: Frontiers in immunology Vol. 11; p. 276
• Main Authors: Janelle, Valérie, Rulleau, Caroline, Del Testa, Simon, Carli, Cédric, Delisle, Jean-Sébastien
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 21-02-2020
• Subjects: Animals; Antigens, Neoplasm - immunology; Genetic Engineering; Hematologic Neoplasms - immunology; Hematologic Neoplasms - therapy; histocompatibility antigens; Humans; Immunology; Immunotherapy - methods; Receptors, Antigen, T-Cell - genetics; T-cell immunotherapy; T-Lymphocytes - immunology; transgenic T-cell receptors; tumor-associated antigens (TAA); tumor-specific antigens (TSA); viral antigens; chimeric antigen receptor (CAR); histocompatibility antigens; tumor-associated antigens (TAA); viral antigens; tumor-specific antigens (TSA); T-cell immunotherapy; allogeneic stem cell transplant; transgenic T-cell receptors
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2020.00276

Over the last decades, T-cell immunotherapy has revealed itself as a powerful, and often curative, strategy to treat blood cancers. In hematopoietic cell transplantation, most of the so-called graft-vs.-leukemia (GVL) effect hinges on the recognition of histocompatibility antigens that reflect immunologically relevant genetic variants between donors and recipients. Whether other variants acquired during the neoplastic transformation, or the aberrant expression of gene products can yield antigenic targets of similar relevance as the minor histocompatibility antigens is actively being pursued. Modern genomics and proteomics have enabled the high throughput identification of candidate antigens for immunotherapy in both autologous and allogeneic settings. As such, these major histocompatibility complex-associated tumor-specific (TSA) and tumor-associated antigens (TAA) can allow for the targeting of multiple blood neoplasms, which is a limitation for other immunotherapeutic approaches, such as chimeric antigen receptor (CAR)-modified T cells. We review the current strategies taken to translate these discoveries into T-cell therapies and propose how these could be introduced in clinical practice. Specifically, we discuss the criteria that are used to select the antigens with the greatest therapeutic value and we review the various T-cell manufacturing approaches in place to either expand antigen-specific T cells from the native repertoire or genetically engineer T cells with minor histocompatibility antigen or TSA/TAA-specific recombinant T-cell receptors. Finally, we elaborate on the current and future incorporation of these therapeutic T-cell products into the treatment of hematological malignancies.